DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,044 filers reported holding DANAHER CORPORATION in Q1 2016. The put-call ratio across all filers is 0.83 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $558,665 | -29.4% | 2,236 | -29.4% | 0.01% | -25.0% |
Q1 2024 | $791,113 | -12.9% | 3,168 | -19.3% | 0.01% | -20.0% |
Q4 2023 | $908,241 | -73.2% | 3,926 | -71.2% | 0.01% | -74.4% |
Q3 2023 | $3,387,309 | -19.9% | 13,653 | -22.6% | 0.04% | -11.4% |
Q2 2023 | $4,231,200 | -3.4% | 17,630 | +1.5% | 0.04% | -6.4% |
Q1 2023 | $4,378,187 | -3.8% | 17,371 | +1.3% | 0.05% | -4.1% |
Q4 2022 | $4,551,953 | -17.8% | 17,150 | -20.0% | 0.05% | -24.6% |
Q3 2022 | $5,538,000 | +3.5% | 21,440 | +1.6% | 0.06% | +10.2% |
Q2 2022 | $5,350,000 | -14.1% | 21,104 | -0.6% | 0.06% | +5.4% |
Q1 2022 | $6,229,000 | -10.1% | 21,235 | +0.9% | 0.06% | -5.1% |
Q4 2021 | $6,925,000 | +8.3% | 21,048 | +0.2% | 0.06% | +3.5% |
Q3 2021 | $6,396,000 | +13.0% | 21,010 | -0.4% | 0.06% | +18.8% |
Q2 2021 | $5,660,000 | +27.6% | 21,090 | +7.1% | 0.05% | +23.1% |
Q1 2021 | $4,434,000 | +4.0% | 19,699 | +2.6% | 0.04% | -2.5% |
Q4 2020 | $4,265,000 | -4.8% | 19,201 | -7.7% | 0.04% | -20.0% |
Q3 2020 | $4,481,000 | +40.5% | 20,811 | +15.4% | 0.05% | +38.9% |
Q2 2020 | $3,189,000 | +38.9% | 18,035 | +8.7% | 0.04% | +33.3% |
Q1 2020 | $2,296,000 | +1.0% | 16,586 | +11.9% | 0.03% | +50.0% |
Q4 2019 | $2,274,000 | +64.3% | 14,818 | +54.7% | 0.02% | +50.0% |
Q3 2019 | $1,384,000 | +3.6% | 9,580 | +2.5% | 0.01% | +20.0% |
Q2 2019 | $1,336,000 | +9.0% | 9,347 | +0.6% | 0.01% | +11.1% |
Q1 2019 | $1,226,000 | +27.2% | 9,287 | -0.7% | 0.01% | +12.5% |
Q4 2018 | $964,000 | -3.6% | 9,350 | +1.6% | 0.01% | +14.3% |
Q3 2018 | $1,000,000 | +9.3% | 9,200 | -0.8% | 0.01% | +16.7% |
Q2 2018 | $915,000 | -5.7% | 9,270 | -6.5% | 0.01% | -14.3% |
Q1 2018 | $970,000 | +4.9% | 9,910 | -0.6% | 0.01% | +16.7% |
Q4 2017 | $925,000 | +4.6% | 9,965 | -3.3% | 0.01% | +20.0% |
Q3 2017 | $884,000 | -1.3% | 10,305 | -2.9% | 0.01% | -16.7% |
Q2 2017 | $896,000 | -2.1% | 10,616 | -0.7% | 0.01% | 0.0% |
Q1 2017 | $915,000 | +5.1% | 10,696 | -4.5% | 0.01% | 0.0% |
Q4 2016 | $871,000 | +3.3% | 11,196 | +4.1% | 0.01% | +20.0% |
Q3 2016 | $843,000 | -61.6% | 10,751 | -50.6% | 0.01% | -66.7% |
Q2 2016 | $2,197,000 | +5.8% | 21,751 | -0.7% | 0.02% | +7.1% |
Q1 2016 | $2,077,000 | +938.5% | 21,900 | +721.1% | 0.01% | +1300.0% |
Q1 2014 | $200,000 | -23.7% | 2,667 | -21.6% | 0.00% | 0.0% |
Q4 2013 | $262,000 | +11.0% | 3,400 | 0.0% | 0.00% | 0.0% |
Q3 2013 | $236,000 | +9.8% | 3,400 | 0.0% | 0.00% | 0.0% |
Q2 2013 | $215,000 | – | 3,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |